MA40458A - Méthodes de traitement du cancer du col de l'utérus - Google Patents
Méthodes de traitement du cancer du col de l'utérusInfo
- Publication number
- MA40458A MA40458A MA040458A MA40458A MA40458A MA 40458 A MA40458 A MA 40458A MA 040458 A MA040458 A MA 040458A MA 40458 A MA40458 A MA 40458A MA 40458 A MA40458 A MA 40458A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- cervical cancer
- treating cervical
- cervical tumor
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 206010008342 Cervix carcinoma Diseases 0.000 title 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 title 1
- 201000010881 cervical cancer Diseases 0.000 title 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 abstract 3
- 241000701806 Human papillomavirus Species 0.000 abstract 1
- 208000009608 Papillomavirus Infections Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
Abstract
La présente invention concerne le traitement d'une tumeur du col de l'utérus provoquée par une infection à papillomavirus humain (hpv). En particulier, l'invention concerne des méthodes pour améliorer le traitement de tumeurs du col de l'utérus et des méthodes pour le traitement des tumeurs du col de l'utérus provoquée par une infection par le hpv à l'aide d'un polynucléotide codant pour une protéine de fusion e6/e7.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462038134P | 2014-08-15 | 2014-08-15 | |
US201462039270P | 2014-08-19 | 2014-08-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40458A true MA40458A (fr) | 2016-02-18 |
Family
ID=55303926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040458A MA40458A (fr) | 2014-08-15 | 2015-08-14 | Méthodes de traitement du cancer du col de l'utérus |
Country Status (11)
Country | Link |
---|---|
US (2) | US11135262B2 (fr) |
EP (1) | EP3193905B1 (fr) |
JP (2) | JP2017525760A (fr) |
KR (1) | KR102523984B1 (fr) |
CN (1) | CN107073070A (fr) |
AU (1) | AU2015302930C1 (fr) |
BR (1) | BR112017002809A2 (fr) |
CA (1) | CA2957128C (fr) |
MA (1) | MA40458A (fr) |
MX (1) | MX2017002081A (fr) |
WO (1) | WO2016024255A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11135262B2 (en) * | 2014-08-15 | 2021-10-05 | Genexine, Inc. | Methods of treating cervical cancer |
CN106632694B (zh) * | 2017-01-24 | 2021-02-12 | 南京益康生物医药有限公司 | 一种重组蛋白及药物组合物与应用 |
JP2021512950A (ja) | 2018-02-02 | 2021-05-20 | エスエル・ベクシジェン・インコーポレイテッドSl Vaxigen, Inc. | 新規なワクチンの免疫補助剤 |
WO2019151760A1 (fr) * | 2018-02-02 | 2019-08-08 | 주식회사 에스엘백시젠 | Nouvelle composition vaccinale multivalente contre le hpv |
MX2020008479A (es) * | 2018-02-14 | 2020-11-24 | Viela Bio Inc | Anticuerpos frente al ligando del receptor de tirosina cinasa 3 similar al sarcoma de mcdonough felino (fms) (flt3l) y tratamiento de enfermedades autoinmunes e inflamatorias. |
US20210024586A1 (en) * | 2018-03-06 | 2021-01-28 | Precigen, Inc. | Human papillomavirus vaccines and uses of the same |
US20210231683A1 (en) * | 2018-04-20 | 2021-07-29 | Unm Rainforest Innovations | Rap1-GTP, Rac1-GTP and FMS-like Tyrosine Kinase 3 ligand (FLT3-L) As Biomarkers For Early Detection of Sepsis |
EP3860316A1 (fr) * | 2020-01-30 | 2021-08-04 | Erbe Elektromedizin GmbH | Plasmas, médias, espèces, systèmes, procédés |
KR20220109444A (ko) * | 2020-04-24 | 2022-08-04 | 주식회사 제넥신 | 자궁경부암 치료방법 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
EP0832981A1 (fr) | 1987-02-17 | 1998-04-01 | Pharming B.V. | Séquences d'ADN pour diriger des protéines vers les glandes mammaires, afin d'être secrétées efficacement |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
AUPN015794A0 (en) | 1994-12-20 | 1995-01-19 | Csl Limited | Variants of human papilloma virus antigens |
KR100201584B1 (ko) | 1996-07-12 | 1999-06-15 | 손경식 | 사람 파필로마 바이러스 18형 이6 단백질에 대한 인체의 면역성 조절 기능을 갖는 펩타이드 |
GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
PT1214097E (pt) | 1999-09-16 | 2009-10-19 | Eisai Inc | Ácidos nucleicos que codificam polipéptidos de poliepitopos |
EP1243655B1 (fr) | 2001-03-23 | 2007-02-21 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Gènes et protéines E6 et E7 modifies comme vaccin |
KR100900249B1 (ko) | 2001-12-07 | 2009-05-29 | 포항공과대학교 산학협력단 | SIVmac239의 면역원성 플라스미드 및 이들을 함유한AIDS DNA 백신 |
ES2391451T3 (es) | 2002-10-03 | 2012-11-26 | Wyeth Holdings Corporation | Péptidos de fusión que comprenden los polipéptidos E7 y E6 de virus del papiloma humano y composiciones inmunogénicas de los mismos |
CN1299769C (zh) | 2005-01-31 | 2007-02-14 | 中国医学科学院肿瘤医院肿瘤研究所 | 人乳头瘤病毒和热休克蛋白重组蛋白疫苗及其用途 |
ATE521626T1 (de) | 2005-08-24 | 2011-09-15 | Healthbanks Biotech Co Ltd | Fusionsprotein zur inhibierung von gebärmutterhalskrebs |
US7732166B2 (en) * | 2005-11-15 | 2010-06-08 | Oncohealth Corporation | Detection method for human pappilomavirus (HPV) and its application in cervical cancer |
EP2010572B1 (fr) | 2006-04-19 | 2013-10-23 | POSTECH Academy-Industry Foundation | Proteines hybrides contenant des polypeptides hpv et des peptides d'immunostimulation pour le traitement et la prévention du cancer du col de l'utérus |
WO2008046251A1 (fr) * | 2006-10-19 | 2008-04-24 | Sunbio Biotech Pharmaceuticals(Tianjin) Co., Ltd. | Protéines hybrides contenant un domaine n de la calréticuline humaine et des protéines e6 ou e7 du papillomavirus humain de type 16, et utilisations associées |
DE102008010954A1 (de) | 2008-02-25 | 2009-08-27 | Cichon, Günter, Prof.Dr. | DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen |
KR101166516B1 (ko) * | 2009-07-02 | 2012-07-20 | 주식회사 바이오드 | 사람 파필로마바이러스 변형체 및 면역 증강제를 포함하는 자궁경부암 예방 또는 치료용 조성물 |
EP2377879A1 (fr) * | 2010-04-14 | 2011-10-19 | Deutsches Krebsforschungszentrum | Protéines de fusion HPV E7 à terminaison N |
US9000139B2 (en) | 2010-08-13 | 2015-04-07 | Genexine, Inc. | Composition for preventing or treating cervical cancer having human papillomavirus plasmodium and immunity enhancer |
CN102154325B (zh) * | 2011-01-01 | 2013-08-21 | 上海生物制品研究所有限责任公司 | 针对人乳头瘤状病毒的疫苗及其制法和用途 |
WO2013092875A1 (fr) | 2011-12-21 | 2013-06-27 | Vaccibody As | Vaccins contre le hpv |
US11135262B2 (en) * | 2014-08-15 | 2021-10-05 | Genexine, Inc. | Methods of treating cervical cancer |
-
2015
- 2015-08-14 US US15/503,997 patent/US11135262B2/en active Active
- 2015-08-14 MX MX2017002081A patent/MX2017002081A/es unknown
- 2015-08-14 BR BR112017002809A patent/BR112017002809A2/pt not_active Application Discontinuation
- 2015-08-14 KR KR1020177007096A patent/KR102523984B1/ko active IP Right Grant
- 2015-08-14 JP JP2017527988A patent/JP2017525760A/ja active Pending
- 2015-08-14 CA CA2957128A patent/CA2957128C/fr active Active
- 2015-08-14 MA MA040458A patent/MA40458A/fr unknown
- 2015-08-14 EP EP15832334.5A patent/EP3193905B1/fr active Active
- 2015-08-14 AU AU2015302930A patent/AU2015302930C1/en active Active
- 2015-08-14 WO PCT/IB2015/056214 patent/WO2016024255A1/fr active Application Filing
- 2015-08-14 CN CN201580053391.6A patent/CN107073070A/zh active Pending
-
2021
- 2021-04-28 JP JP2021076283A patent/JP7355399B2/ja active Active
- 2021-08-27 US US17/459,460 patent/US20220096589A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2015302930B2 (en) | 2020-11-26 |
US20220096589A1 (en) | 2022-03-31 |
BR112017002809A2 (pt) | 2017-12-19 |
KR20170045254A (ko) | 2017-04-26 |
US20170304385A1 (en) | 2017-10-26 |
WO2016024255A1 (fr) | 2016-02-18 |
JP7355399B2 (ja) | 2023-10-03 |
CA2957128C (fr) | 2023-09-26 |
CN107073070A (zh) | 2017-08-18 |
US11135262B2 (en) | 2021-10-05 |
AU2015302930A1 (en) | 2017-02-23 |
EP3193905A1 (fr) | 2017-07-26 |
EP3193905B1 (fr) | 2024-04-03 |
AU2015302930C1 (en) | 2023-06-01 |
KR102523984B1 (ko) | 2023-04-20 |
CA2957128A1 (fr) | 2016-02-18 |
MX2017002081A (es) | 2017-05-23 |
JP2017525760A (ja) | 2017-09-07 |
JP2021119174A (ja) | 2021-08-12 |
EP3193905A4 (fr) | 2018-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
MA40458A (fr) | Méthodes de traitement du cancer du col de l'utérus | |
MX2021006581A (es) | Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia. | |
MX2018012880A (es) | Metodos para proporcionar arn de hebra sencilla. | |
MX2021013837A (es) | Enfoque de inmunoterapias de combinacion para el tratamiento del cancer. | |
MX2022007522A (es) | Anticuerpos anti-cd27. | |
GB2541571A (en) | Pharmaceutical compositions | |
GEP20217317B (en) | Combination therapy for the treatment of cancer | |
NZ723884A (en) | Methods of treating alzheimer’s disease | |
MX2018001755A (es) | Vacuna contra viruela para tratamiento del cancer. | |
EP4353320A3 (fr) | Utilisation de plasma sanguin et fractions de plasma sanguin en tant que therapie pour lutter contre la croissance et la progression tumorale | |
MX2017000306A (es) | Metodos para tratar hipotension. | |
MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
MX2023007706A (es) | Nanoparticulas para su uso como vacuna terapeutica. | |
WO2013162981A3 (fr) | Écarteurs d'implants mammaires pour le traitement des infections périprothétiques des implants mammaires | |
MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
GB2546703A (en) | Compounds | |
MA39718A (fr) | Compositions et méthodes d'utilisation de celles-ci | |
UA107743C2 (ru) | Способ лечения аденокарциномы |